Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Dec 03, 2015 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | -- | |
| Sep 15, 2015 | Chief Science Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 25,000 | $17.75 | 720,953 | |
| Jun 01, 2015 | VP Global Marketing | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 25,000 | -- | 25,000 | |
| May 08, 2015 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | 25,000 | |
| May 08, 2015 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | 25,000 | |
| May 08, 2015 | SVP, Program Management | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | 25,000 | |
| May 08, 2015 | SVP, Program Management | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | 25,000 | |
| May 08, 2015 | SVP, Technical Operations | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | 25,000 | |
| May 08, 2015 | SVP, Technical Operations | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | 25,000 | |
| May 08, 2015 | SVP, Chief Patient Advocate | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 25,000 | -- | 25,000 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.